Formation of hypertrophic scars: evolution and susceptibility
- PMID: 22471257
- DOI: 10.3109/2000656X.2012.669184
Formation of hypertrophic scars: evolution and susceptibility
Abstract
Formation of hypertrophic scars is a common complication of wound healing, and at present little is known about the incidence and risk factors. Our aim was to analyse the incidence, progression, and regression of postoperative hypertrophic scars over time and to identify risk factors of hypertrophic scars. Patients who had had bilateral reduction mammoplasty or median sternotomy incision were included in the study. All patients were examined at 3 and 12 months postoperatively. We recorded: height, weight, allergy status, smoking status, skin type, tanning, and shape of the scar 3 and 12 months postoperatively. Of the 204 patients who were included, 122 (60%) developed a hypertrophic scar within 12 months of operation. Of these patients, 117 (96%) developed a hypertrophic scar within 3 months of operation. Twelve months postoperatively, 66/204 patients (32%) had a hypertrophic scar. In 31 of the 66 of the patients with a hypertrophic scar 3 months postoperatively (47%), the hypertrophic scar(s) regressed after 3 and 12 months. Smoking and age were associated with formation of hypertrophic scars. In conclusion, 60% of patients developed hypertrophic scars postoperatively, typically during the first three months. Most hypertrophic scars that are present after three months are still hypertrophic after 12 months. Young, non-smoking patients are more susceptible to formation of hypertrophic scars.
Similar articles
-
Perioperative conditions affect long-term hypertrophic scar formation.Ann Plast Surg. 2010 Sep;65(3):321-5. doi: 10.1097/SAP.0b013e3181c60f88. Ann Plast Surg. 2010. PMID: 20733369
-
Median sternotomy scar assessment.N Z Med J. 2011 Nov 25;124(1346):57-62. N Z Med J. 2011. PMID: 22143853
-
Topical calcipotriol for preventive treatment of hypertrophic scars: a randomized, double-blind, placebo-controlled trial.Arch Dermatol. 2009 Nov;145(11):1269-75. doi: 10.1001/archdermatol.2009.237. Arch Dermatol. 2009. PMID: 19917956 Clinical Trial.
-
Hypertrophic scar.Phys Med Rehabil Clin N Am. 2011 May;22(2):301-10, vi. doi: 10.1016/j.pmr.2011.02.002. Phys Med Rehabil Clin N Am. 2011. PMID: 21624722 Review.
-
Management of scar contractures, hypertrophic scars, and keloids.Otolaryngol Clin North Am. 1995 Oct;28(5):1057-68. Otolaryngol Clin North Am. 1995. PMID: 8559572 Review.
Cited by
-
The Complexity of the Post-Burn Immune Response: An Overview of the Associated Local and Systemic Complications.Cells. 2023 Jan 17;12(3):345. doi: 10.3390/cells12030345. Cells. 2023. PMID: 36766687 Free PMC article. Review.
-
Natural products for the treatment of hypertrophic scars: Preclinical and clinical studies.Heliyon. 2024 Aug 30;10(17):e37059. doi: 10.1016/j.heliyon.2024.e37059. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39296083 Free PMC article. Review.
-
Scarring Skin: Mechanisms and Therapies.Int J Mol Sci. 2024 Jan 25;25(3):1458. doi: 10.3390/ijms25031458. Int J Mol Sci. 2024. PMID: 38338767 Free PMC article. Review.
-
Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study.Toxins (Basel). 2023 Oct 31;15(11):636. doi: 10.3390/toxins15110636. Toxins (Basel). 2023. PMID: 37999499 Free PMC article. Clinical Trial.
-
Prognostic tools for hypertrophic scar formation based on fundamental differences in systemic immunity.Exp Dermatol. 2021 Jan;30(1):169-178. doi: 10.1111/exd.14139. Epub 2020 Aug 17. Exp Dermatol. 2021. PMID: 32618380 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical